Dynavax Technologies Co. (NASDAQ:DVAX) Shares Bought by Trexquant Investment LP

Trexquant Investment LP grew its holdings in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 48.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 776,397 shares of the biopharmaceutical company's stock after buying an additional 254,405 shares during the quarter. Trexquant Investment LP owned 0.59% of Dynavax Technologies worth $9,915,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Franklin Resources Inc. raised its position in Dynavax Technologies by 5.2% during the fourth quarter. Franklin Resources Inc. now owns 86,675 shares of the biopharmaceutical company's stock worth $1,107,000 after acquiring an additional 4,260 shares during the period. O Shaughnessy Asset Management LLC acquired a new position in shares of Dynavax Technologies during the 4th quarter worth about $131,000. Norges Bank purchased a new position in Dynavax Technologies in the 4th quarter valued at about $7,762,000. WINTON GROUP Ltd boosted its holdings in Dynavax Technologies by 339.0% in the 4th quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company's stock worth $5,450,000 after buying an additional 329,579 shares during the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in shares of Dynavax Technologies during the fourth quarter valued at approximately $883,000. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Trading Down 2.3 %

Shares of NASDAQ DVAX traded down $0.29 during trading on Monday, reaching $12.37. The stock had a trading volume of 738,158 shares, compared to its average volume of 2,145,521. The business's 50-day moving average price is $13.37 and its 200-day moving average price is $12.56. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The company has a market cap of $1.53 billion, a P/E ratio of 68.34 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The business had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. On average, equities research analysts predict that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on DVAX shares. HC Wainwright reiterated a "buy" rating and set a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Monday, February 24th. Finally, The Goldman Sachs Group cut Dynavax Technologies from a "neutral" rating to a "sell" rating and cut their price target for the company from $15.00 to $12.00 in a report on Tuesday, February 11th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.